• June 3-6, 2024
  • San Diego Convention Center, California



SIRPant Immunotherapeutics Inc

Wednesday, June 05, 2024
Company Presentation
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 1
SIRPant Immunotherapeutics Inc. is a clinical stage company focused on the development of novel autologous macrophage cell therapy for treatment of aggressive tumors with unmet medical needs. SIRPant employs first-in-class macrophage-based cellular immunotherapy to drive robust and lasting immune responses that leverage downstream polyclonal killer T cells and polyclonal antibodies to target the tumor neo-antigens. In contrast to other forms of cellular immunotherapy, SIRPant utilizes a multi-pronged approach that engages multiple effector pathways simultaneously to elicit immunological response to treat cancer in a completely novel way. The company’s lead candidate is an autologous SIRPα-low activated macrophage therapy for the treatment of non-Hodgkin’s Lymphoma (NHL), under which the company intends to dose the first patient in Q4 2023. In Q4 2023 SIRPant filed a second IND for solid tumors.
SIRPant Immunotherapeutics Inc
Company Website: http://www.sirpantimmunotx.com
Lead Product in Development: SIRPant-M™ Autologous Sirpα-low Activated Macrophage
Number Of Unlicensed Products (For Which You Are Seeking Partners): Two

Company HQ City


Company HQ State


Company HQ Country

United States

CEO/Top Company Official

Robert J Towarnicki

Development Phase of Primary Product

Phase I
Primary Speaker
Robert Towarnicki, MS
President & CEO
SIRPant Immunotherapeutics Inc.
Back to Session List

white squarewhite


Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.